 Nanomedicine is important in cancer therapy, but loading, drug release, and therapeutic effectiveness issues limit the translation to the clinic. Here, authors report a full API nanodrug with an ideal API content and pH-responsive release for continuous spatiotemporal cancer therapy based on PPI-XMCO-FE2-PLUS-PVPR metabolic pathway. This article was authored by Fang Fang, Xia Wang, Gea Song, and others.